Oxigene Receives Fast Track Designation From U.S. FDA for CA4P
30. März 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Reports 2015 Financial Results
28. März 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Receives European Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
25. März 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 25, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Appoints Dr. Simon Pedder to Board of Directors
24. März 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Announces Upcoming Presentation at the BIO-CEO Conference and Provides Business Update
03. Februar 2016 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Neuroendocrine Tumors
06. Januar 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Receives European Orphan Drug Designation for OXi4503 to Treat Acute Myeloid Leukemia
17. Dezember 2015 15:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer,...
OXiGENE Reports Third Quarter 2015 Financial Results
10. November 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
OXiGENE Announces Positive Initial Data From Phase 1b Study of CA4P in Combination With Pazopanib in Patients With Advanced Recurrent Ovarian Cancer
05. November 2015 16:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today...
OXiGENE Announces Initiation of Phase 1b/2 Clinical Trial of OXi4503 in Acute Myeloid Leukemia
21. Oktober 2015 16:15 ET
|
Mateon Therapeutics
First patient dosed in OXiGENE-sponsored expansion of investigator trial
Phase 1b/2 dose-escalation study of OXi4503 as a single agent and in combination with cytarabine
SOUTH SAN...